ArticleTranslational cancer research2025
Immunocytochemical staining for p16, Ki-67, and MCM2 in the detection of cervical lesions and cancer: a prospective observational study.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer remains a significant global health concern, necessitating effective screening strategies. Traditional methods, such as liquid-based cytology (LBC) and high-risk human papillomavirus (HR-HPV) testing, have limitations in sensitivity and specificity. This study aimed to evaluate the diagnostic performance of p16, Ki-67, and minichromosome maintenance protein 2 (MCM2) as biomarkers in cervical cancer screening, both as standalone methods and in combination, to improve early detection and risk stratification. Methods: This prospective study included 344 women who underwent LBC and HR-HPV testing, followed by the gold standard of colposcopy and biopsy. Immunocytochemical (ICC) staining for p16, Ki-67, and MCM2 was performed. The sensitivity, specificity, and Youden index were calculated to compare the efficacy of the single and combined screening methods. Results: LBC alone demonstrated suboptimal sensitivity, while HR-HPV testing exhibited low specificity. Among the single methods, dual staining of p16 paired with MCM2 (p16/MCM2) when using a high-risk threshold achieved the highest Youden index (0.55). The combination of LBC with p16/MCM2 yielded superior sensitivity (96.3%) and moderate specificity (42.6%), outperforming the combination of HR-HPV with dual staining of p16/MCM2. Importantly, all missed diagnoses were high-grade squamous intraepithelial lesion (HSIL) with cervical intraepithelial neoplasia (CIN) grades 2-3, and no cases of cervical cancer were missed. Conclusions: HR-HPV-based primary screening with p16/Ki-67 triage may offer a viable strategy for cervical cancer detection. Combining LBC with p16/MCM2 dual staining demonstrated improved sensitivity and specificity compared to conventional methods. Notably, p16/MCM2 as a standalone assay achieved the highest Youden index when using a high-risk threshold. Further validation through multicenter studies is essential to confirm its generalizability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.